Madden Orlovsky who has autism, breaks into "You've Got a Friend in Me" while his father Dan watches on with tears in his eyes.
This was to honor Autism Awareness Day and the best thing you’ll see today
Appreciate the reporting and the due diligence. As a parent and former high school teacher, though, I’m excited about this option and others like it coming to market. Sharp people are hoping public school leaders are paying attention. With the job market changing faster than most realize, Alpha is at least a clear signal of the direction education needs to move if we want the next generation to be prepared. Thank you again, but even reading this article it doesn’t change our family’s hope for a brick-and-mortar option coming to Pittsburgh very soon!
Matt Bielski @DefianceCEO sat down with Eric Balchunas and Scarlet Fu on @BloombergTV to share his son Lev’s life with profound autism and their family’s experience with L1-79, an investigational treatment aimed at the core social symptoms of autism.
The conversation also covered the Defiance Autism Impact ETF (ASD), a sign that more attention and capital are starting to move into the space.
L1-79 is still investigational and advancing toward Phase 3 trials. Seeing it discussed on a national stage is a meaningful step forward.
#autism #autismtreatment #autismawareness #l179
We seriously need to discuss the use of AI in scientific peer review.
Yesterday, we prepared a ~15-page response to a reviewer. We addressed every comment individually and revised the manuscript accordingly.
About 12 hours later, the same reviewer came back with another 2 pages of comments. And these were not simply an assessment of whether we had adequately addressed the original concerns. There were new analyses, new technical details, and new requests that had never been raised in the first round.
Is it humanly possible to carefully read a 15-page response letter, check the revised manuscript and all the changes, critically evaluate them, and then develop an entirely new set of methodological requests within 12 hours?
Perhaps. But it certainly raises questions.
With AI, you can generate an endless list of things authors “could also do”:
“Please perform this subgroup analysis.”
“Add another sensitivity analysis.”
“Repeat the analysis using a different model.”
“Adjust for this additional variable.”
“Validate the findings using another statistical method.”
There is literally no end to this.
And this is not just about whether reviewers use AI. The bigger problem is peer review turning into moving goalposts. Authors address the first-round concerns, only to find that the goalposts have moved and an entirely new set of requests appears in the next round.
Journals need clear rules for AI-assisted peer review. AI use should be disclosed, and unless a genuinely new and critical issue is identified, subsequent review rounds should primarily assess whether the original concerns were adequately addressed.
Otherwise, peer review risks becoming an endless AI prompt loop rather than scientific evaluation.
I fully recognize how difficult it has become for journals to find reviewers, and I am among those who criticize many aspects of the current academic publishing system. But please, if you volunteer to review a paper, don’t make an already exhausting process even more exhausting for authors. Enough is enough.
Shane Bieber never looked like an ace. 91-93 mph, no electric stuff. But he won a Cy Young. Here's why that makes sense.
Most people think you need to throw hard or have nasty stuff to make it to the big leagues. That's not the only path.
The real question is: what elite tool do you have?
For Bieber, it was command. He never walks anybody. That's not a small thing — that's an elite weapon. Pair that with good pitch shapes and you have a real pitcher, even without the velocity.
The honest projection on him coming up was probably a 3 or 4 ERA guy. A solid mid-rotation starter. Nobody was calling him a future ace.
But then something happened. He added velocity. He added more pitch shapes. He developed. And when you stack elite command on top of improved stuff, you get a Cy Young winner.
The lesson here isn't "just throw hard" or "just have good command." It's that you need at least ONE elite tool to have a path. And the fastest path to the big leagues should run through whatever that tool is.
If your one elite tool is velocity, stop trying to develop four average pitches. Throw 100 and get there.
If your one elite tool is command, build around that. The shapes matter more when you can actually locate them.
Bieber is proof that you don't need to look the part. You need to have a real tool and know how to use it.
🌸 THE 10 MOST IMPORTANT BREAST CANCER TRIALS OF #ASCO26
Chicago is loaded this year.
From ctDNA-guided endocrine switching to frontline ADCs and next-gen HER2 platforms, these are the studies most likely to shape breast oncology practice 👇
🩷 HR+ / HER2- DISEASE
1️⃣ persevERA BC (LBA1006)
Giredestrant + palbociclib vs letrozole + palbociclib in 1L metastatic disease
Despite missing the primary PFS endpoint, biomarker/subset analyses may define where oral SERDs still fit.
2️⃣ SERENA-6 (LBA1007)
Camizestrant for emergent ESR1 mutations detected via ctDNA BEFORE radiographic progression
Possibly the biggest ctDNA-guided endocrine strategy discussion of the meeting.
3️⃣ VIKTORIA-1
Gedatolisib + fulvestrant ± palbociclib after AI + CDK4/6i progression
Huge unmet-need population.
Post-CDK4/6 sequencing remains one of the biggest HR+ questions.
4️⃣ lidERA BC (Abstract 502)
Adjuvant giredestrant in early ER+/HER2- disease
Moving oral SERDs into curative-intent therapy.
5️⃣ FOURLIGHT-2 (Abstract 1042)
Next-gen CDK4-selective inhibition with atirmociclib + letrozole
Can we reduce neutropenia while preserving efficacy?
🔥 TNBC & ADC ERA
6️⃣ ASCENT-04 (LBA1000)
Sacituzumab govitecan + pembrolizumab vs chemo + pembrolizumab in PD-L1+ mTNBC
Could ADC + IO combinations become the frontline standard?
7️⃣ TROPION-Breast02
Dato-DXd vs chemotherapy in metastatic TNBC
A major test of the “ADC-first” paradigm.
🎯 HER2+ & NEXT-GEN NEOADJUVANT PLATFORMS
8️⃣ KN026-004 (LBA660)
Novel biparatopic HER2 antibody vs classic CLEOPATRA-style therapy
Watch the pCR data carefully.
9️⃣ I-SPY 2.2 (LBA514)
Rilvegostomig + T-DXd in high-risk HER2-negative disease
IO + ADC combinations continue moving earlier.
🔟 DESTINY-Breast05 Update
Long-term outcomes for T-DXd vs T-DM1 in residual HER2+ disease
Which breast abstract are you watching most closely?
#BCSM #OncoTwitter #ASCO26 #BreastCancer #MedEd @asco@myesmo@esmo_open@OncoAlert@OncBrothers
Cancer survival in the U.S. just crossed 70%.
It was 63% in the 1990s.
That gap = 4.8M people alive today.
This one chart captures survival gains across 29 cancer types.
The wins are real.
So is the unfinished work.
▪️CML: 31% → 72%
▪️Multiple myeloma: 32% → 62%
▫️Kidney: 59% → 82%
▫️Metastatic melanoma: 16% → 35%
▫️Childhood ALL: 80% → 92%
But some cancers barely moved.
Cervical cancer outcomes actually worsened.
None of this is abstract progress, though.
These are birthdays, grandkids, and years of life returned.
This is what funded science does.
Next time someone asks if cancer research works, show them this (full) chart.
- - - - -
Source: ACS Cancer Statistics 2026 · SEER · 𝘷𝘪𝘢 @Jori_health
- - - - -
@KingFish626 We had meetings with the administration about this as far back as 2012 in the smaller school settings. Still, with very little action taken.
How Agendia’s breast cancer assays are testing the limits of race-based clinical assumptions https://t.co/h5FdnQYSTV Race matters in care access, but tumor biology may drive response. Agendia’s FLEX data sharpen the breast cancer equity debate. #Agendia#MammaPrint#BluePrint #BreastCancer #PrecisionOncology #GenomicTesting #OncologyDiagnostics #ASBrS2026 #CancerResearch #HealthEquity @Agendia
The largest youth sports operator in America just hired Goldman Sachs to find a buyer.
2 million athletes. 1,500 events. $40 million in annual profit.
The next time someone tells you youth sports are about the kids, remember: kids don't have an investment banker.
Attending #ASBrS? Don't miss our breakfast symposium featuring Mehran Habibi, MD!
🔗 RSVP today: https://t.co/MNJDUlX7qp
At the symposium:
➡️Hear real‑world cases and the latest neoadjuvant data
➡️Learn how MammaPrint® + BluePrint® genomic insights can:
✨Inform neoadjuvant planning
✨Guide surgical decision‑making in early‑stage breast cancer
➡️Discover how surgeons can personalize treatment by leading with tumor biology
📅 Friday, May 1, 2026
🕡 6:30��7:45am (breakfast available at 6:15am)
📍 Room 608–610 | Seattle Convention Center | ASBrS
"Success for me is that we transform education for one billion kids so that it is nothing like what we had. Our job is to make this the best time in history to be a five-year-old."
In this video, Dr. Habibi shares how genomics can help inform surgical decision‑making in early-stage ER+/HER2‑ breast cancer—especially when axillary surgery may become extensive and significantly impact patients. Genomic insights can help guide which patients may benefit from systemic therapy first versus surgery upfront.
▶️ Watch here: https://t.co/ghz8AH39Sf
📢📖New study published in npj Breast Cancer:
Newly published research in #npjBCancer demonstrates that MammaPrint® + BluePrint® genomic profiling identifies aggressive tumor subtypes more frequently observed in Black females, while showing comparable outcomes across races when treatment is guided by genomic results.
👩💻Read the announcement: https://t.co/UtSrwa0PPC
#Genomics #BreastCancer #PrecisionOncology #MammaPrint